Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19912248 | 1.00 | CYP3A4 (0.45) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL19912253 | 1.00 | CYP3A4 (0.45) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL14802705 | 0.91 | CYP3A4 (0.41) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL19699812 | 0.91 | CYP3A4 (0.41) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL2522278 | 0.89 | CYP3A4 (0.50) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL2598173 | 0.88 | CYP3A4 (0.45) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL20278340 | 0.88 | TSHR (0.41) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL19511962 | 0.88 | TSHR (0.41) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL20261782 | 0.87 | PLA2G2A (0.39) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 | |
| SCHEMBL20261774 | 0.87 | PLA2G2A (0.39) | CYP3A4TSHRPLA2G2ALPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059147-A1 | METHOD FOR SITE-SELECTIVELY CLEAVING TARGET NUCLEIC ACID | THE UNIVERSITY OF TOKYO (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059147-A1 | METHOD FOR SITE-SELECTIVELY CLEAVING TARGET NUCLEIC ACID | CPSF6, ADAR, NSUN2 | CYP3A4 2649/4885TSHR 3606/4885PLA2G2A 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.